0.05Open0.05Pre Close0 Volume22 Open Interest2.50Strike Price0.00Turnover105.25%IV40.11%PremiumDec 20, 2024Expiry Date0.00Intrinsic Value100Multiplier30DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.1887Delta0.4893Gamma36.40Leverage Ratio-0.0025Theta0.0002Rho6.87Eff Leverage0.0014Vega
Akebia Therapeutics Stock Discussion
3 mins ago
Akebia Therapeutics Signs Commercial Supply Contract With Leading Dialysis Organization to Enable Access to Vafseo® (Vadadustat) for Patients on Dialysis! Expected to be available in USA in January 2025
Designed to help dialysis organizations incorporate new treatments into their practices, TDAPA provides two years of reimbursement in addition to the ESRD bundled rate
A HCPCS code has also been assig...
Akebia Therapeutics Inc - Contract Enables Prescription of Vafseo for Dialysis Patients From Jan 2025
No comment yet